Abstract:Opioid G protein-coupled receptors (GPCRs) have been implicated in modulating pain, addiction, psychotomimesis, mood and memory, among other functions. We have employed the recently reported crystal structure of the human κ-opioid receptor (κ-OR) and performed molecular dynamics (MD), free energy, and ab initio calculations to elucidate the binding mechanism in complexes with antagonist JDTic and agonist SalA. The two systems were modeled in water and in DPPC lipid bilayers, in order to investigate the effect of the membrane upon conformational dynamics. MD and Atoms in Molecules (AIM) ab initio calculations for the complexes in water showed that each ligand was stabilized inside the binding site of the receptor through hydrogen bond interactions that involved residues Asp138 (with JDTic) and Gln115, His291, Leu212 (with SalA). The static description offered by the crystal structure was overcome to reveal a structural rearrangement of the binding pocket, which facilitated additional interactions between JDTic and Glu209/Tyr139. The role of Glu209 was emphasized, since it belongs to an extracellular loop that covers the binding site of the receptor and is crucial for ligand entrapment. The above interactions were retained in membrane complexes (SalA forms additional hydrogen bonds with Tyr139/312), except the Tyr139 interaction, which is abolished in the JDTic complex. For the first time, we report that JDTic alternates between a "V-shape" (stabilized via a water-mediated intramolecular interaction) and a more extended conformation, a feature that offers enough suppleness for effective binding. Moreover, MM-PBSA calculations showed that the more efficient JDTic binding to κ-OR compared to SalA (ΔGJDTic = -31.6 kcal mol(-1), ΔGSalA = -9.8 kcal mol(-1)) is attributed mostly to differences in electrostatic contributions. Importantly, our results are in qualitative agreement with the experiments (ΔGJDTic,exp = -14.4 kcal mol(-1), ΔGSalA,exp = -10.8 kcal mol(-1)). This study provides previously unattainable information on the dynamics of human κ-OR and insight on the rational design of drugs with improved pharmacological properties.

Structure of the µ-opioid receptor–G i protein complex

Structural Basis for Bifunctional Peptide Recognition at Human Δ-Opioid Receptor

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.

Molecular Modeling on Kappa Opioid Receptor and Its Interaction with Nonpeptide Kappa Opioid Agonists

Ligand Efficacy Modulates Conformational Dynamics of the Μ-Opioid Receptor

Structural and dynamic insights into the activation of the μ-opioid receptor by an allosteric modulator

Structures of the Entire Human Opioid Receptor Family

Molecular Recognition of Morphine and Fentanyl by the Human Μ-Opioid Receptor

Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists

Computational Insights into the G-protein-biased Activation and Inactivation Mechanisms of the Μ Opioid Receptor

Molecular Insights into the Allosteric Coupling Mechanism Between an Agonist and Two Different Transducers for Μ-Opioid Receptors.

Ligand and G-protein selectivity in the κ-opioid receptor

Mu-Opioid Receptor Activation in Live Cells

Profiling the proximal proteome of the activated μ-opioid receptor

Elucidation of Conformational States, Dynamics, and Mechanism of Binding in Human κ-Opioid Receptor Complexes

Structural basis of μ-opioid receptor targeting by a nanobody antagonist

Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic

Probing the cooperative mechanism of the μ-δ opioid receptor heterodimer by multiscale simulation.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Oligomerization of MrgC11 and Μ-Opioid Receptors in Sensory Neurons Enhances Morphine Analgesia.

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.